CN115364268A - Dressing for craniocerebral trauma and preparation method thereof - Google Patents
Dressing for craniocerebral trauma and preparation method thereof Download PDFInfo
- Publication number
- CN115364268A CN115364268A CN202211188318.8A CN202211188318A CN115364268A CN 115364268 A CN115364268 A CN 115364268A CN 202211188318 A CN202211188318 A CN 202211188318A CN 115364268 A CN115364268 A CN 115364268A
- Authority
- CN
- China
- Prior art keywords
- dressing
- chitosan
- fiber layer
- craniocerebral trauma
- woven fabric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019196 Head injury Diseases 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229920001661 Chitosan Polymers 0.000 claims abstract description 123
- 239000000835 fiber Substances 0.000 claims abstract description 101
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 84
- 229920002678 cellulose Polymers 0.000 claims abstract description 83
- 239000001913 cellulose Substances 0.000 claims abstract description 83
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000003825 pressing Methods 0.000 claims abstract description 16
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
- 238000002791 soaking Methods 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims abstract description 7
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 230000035699 permeability Effects 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 10
- 229960000723 ampicillin Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229920000180 alkyd Polymers 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- 229960005224 roxithromycin Drugs 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 22
- 208000027418 Wounds and injury Diseases 0.000 abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 21
- 206010052428 Wound Diseases 0.000 abstract description 20
- 238000000338 in vitro Methods 0.000 abstract description 16
- 230000015271 coagulation Effects 0.000 abstract description 12
- 238000005345 coagulation Methods 0.000 abstract description 12
- 230000035876 healing Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 38
- 235000019441 ethanol Nutrition 0.000 description 21
- 230000029663 wound healing Effects 0.000 description 19
- 238000001035 drying Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- IRAQOCYXUMOFCW-CXTNEJHOSA-N cedrene Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@H]1C(C)=CC2 IRAQOCYXUMOFCW-CXTNEJHOSA-N 0.000 description 8
- IRAQOCYXUMOFCW-UHFFFAOYSA-N di-epi-alpha-cedrene Natural products C1C23C(C)CCC3C(C)(C)C1C(C)=CC2 IRAQOCYXUMOFCW-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000004381 surface treatment Methods 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- DJYWGTBEZVORGE-CVWWDKSYSA-N cedr-8(15)-en-9-ol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1C(=C)C(O)C2 DJYWGTBEZVORGE-CVWWDKSYSA-N 0.000 description 2
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 2
- 229940026455 cedrol Drugs 0.000 description 2
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- NCZJHBOLUQWVQK-UHFFFAOYSA-N kaempferol 3-O-rhamnoside Natural products CC1OC(OC2=C(Oc3c(O)cc(O)cc3C2=O)c4ccc(O)cc4)C(O)C(O)C1O NCZJHBOLUQWVQK-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a dressing for craniocerebral trauma and a preparation method thereof; belongs to the field of medicine; the method comprises the following steps: preparing a chitosan fiber layer: dissolving modified chitosan in acetic acid solution to prepare modified chitosan solution; soaking the cellulose non-woven fabric in the modified chitosan solution for ultrasonic treatment, and then placing the cellulose non-woven fabric in a hot press for pressure maintaining and pressing to obtain a chitosan fiber layer; preparing an antibacterial fiber layer: soaking the cellulose non-woven fabric in a solution containing an antibacterial agent for ultrasonic treatment, and then placing the cellulose non-woven fabric in a hot press for pressure maintaining and pressing to obtain an antibacterial fiber layer; preparation of the dressing: fixing the chitosan fiber layer and the antibacterial fiber layer on the outer layer in sequence by adopting a binding wire, sterilizing and packaging to obtain the dressing for craniocerebral trauma. The dressing has good water absorption, antibacterial property and in vitro coagulation property, and also has good healing effect on wound.
Description
Technical Field
The invention belongs to the technical field of dressing preparation, and particularly relates to a dressing for craniocerebral trauma and a preparation method thereof.
Background
Craniocerebral trauma is one of common injuries caused by traffic accidents and other reasons, most consciousness and thinking of patients with craniocerebral trauma coma are obstructed, the will of the patients cannot be effectively expressed, and various reflexes are reduced or even disappear. The craniocerebral trauma coma patient is not sensitive to various feelings and lacks of normal active protection reaction, so the patient is easy to scald when in physical treatment or winter warm keeping.
The medical dressing is used as a covering material of a wound, can replace damaged skin to play a role of temporary barrier in the wound healing process, avoids or controls wound infection, and provides an environment which is favorable for wound healing. The dressing which is most clinically used at present is mainly made of gauze, cotton pads and the like, and is mostly made of cotton, linen and linen, belongs to an inert dressing, and has no obvious promotion effect on the healing of wound surfaces. In the prior art, for example, publication No. CN 109893342A discloses a dressing for craniocerebral trauma and a preparation method thereof, the dressing for craniocerebral trauma sequentially comprises from outside to inside: the fixing layer, the backing layer, the water absorbing layer and the drug layer are arranged on the backing layer at intervals, the drug layer contains kaempferol-3-O-rhamnoside, and the drug layer matrix is selected from: alginate gel, cellulose gel, chitosan gel, etc.; the dressing has the effect of promoting wound healing, and the effect of promoting wound healing is better when the drug layer matrix is chitosan gel containing chitosan oligosaccharide.
Disclosure of Invention
The invention aims to provide a craniocerebral trauma dressing with better water absorption, antibacterial property and in-vitro coagulation property, which has better healing effect on wounds.
The technical scheme adopted by the invention for realizing the purpose is as follows:
a craniocerebral trauma dressing, the dressing structure of which comprises: fixing the outer layer; the chitosan fiber layer is used as a middle layer; the antibacterial fiber layer is used as an inner layer;
the chitosan fiber layer is prepared by soaking cellulose non-woven fabrics in a modified chitosan solution;
the modified chitosan is prepared by alcohol acid modified chitosan of isomango.
According to the invention, the modified chitosan is prepared by using the isomango alcohol acid modified chitosan, and the chitosan fiber layer is prepared by treating the cellulose non-woven fabric, so that the water absorption performance of the chitosan fiber layer is improved; the chitosan fiber layer is combined with the antibacterial fiber layer and the fixed outer layer to prepare the dressing for craniocerebral trauma, and the air permeability and the in-vitro coagulation performance of the dressing for craniocerebral trauma are improved; and can accelerate the healing of the wound.
It should be noted that, in some embodiments of the present invention, the fixing outer layer is made of elastic cotton thread material; the shape is a hat-shaped net structure.
The invention also discloses a preparation method of the dressing for craniocerebral trauma, which comprises the following steps:
s1: preparing a chitosan fiber layer: dissolving modified chitosan in acetic acid solution to prepare modified chitosan solution; soaking the cellulose non-woven fabric into the modified chitosan solution for ultrasonic treatment, and then placing the cellulose non-woven fabric into a hot press for pressure maintaining and pressing to obtain a chitosan fiber layer;
s2: preparing an antibacterial fiber layer: soaking the cellulose non-woven fabric into a solution containing an antibacterial agent for ultrasonic treatment, and then placing the cellulose non-woven fabric into a hot press for pressure maintaining and pressing to obtain an antibacterial fiber layer;
s3: preparation of the dressing: fixing the chitosan fiber layer and the antibacterial fiber layer on the outer layer by adopting a binding wire in sequence, sterilizing and packaging to obtain the dressing for craniocerebral trauma.
It should be noted that, in some embodiments of the present invention, the preparation method of the modified chitosan is: dispersing chitosan in acetic acid solution, completely dissolving at room temperature, adding isomangiferol acid and a condensing agent, stirring at room temperature for reaction, and washing to neutrality to obtain the modified chitosan.
It is further noted that in some embodiments of the present invention, the chitosan is 2.5-5 parts, the acetic acid solution is 20-40 parts, the isomango alcohol acid is 0.5-1.5 parts, and the condensing agent is 0.05-0.1 part by weight.
It should be noted that, in some embodiments of the present invention, the concentration of the modified chitosan solution in step S1 is 20 to 35wt%.
It should be noted that, in some embodiments of the present invention, in step S1, the ultrasonic treatment power is 120-200W, and the ultrasonic treatment time is 15-30min.
In some embodiments of the present invention, in step S1, the holding pressure is 5 to 10MPa, and the pressing time is 30 to 50min.
It should be noted that, in some embodiments of the present invention, in step S2, the antibacterial agent is at least one of ampicillin, cefoperazone, levofloxacin, doxycycline, roxithromycin, azithromycin, ciprofloxacin, and lomefloxacin.
It should be noted that, in some embodiments of the present invention, in step S2, the ultrasonic treatment power is 120-200W, and the ultrasonic treatment time is 15-30min.
The invention also discloses application of the modified chitosan in improving the air permeability of the dressing for craniocerebral trauma.
In order to further improve the antibacterial property of the dressing for craniocerebral trauma and the effect of accelerating wound healing, the preferable measures further comprise: in the process of preparing the antibacterial fiber layer, the cellulose non-woven fabric is firstly modified by adopting cedrene alcohol and then is soaked in an antibacterial agent for surface treatment, so that the modified antibacterial fiber layer is obtained.
It should be noted that, in some embodiments of the present invention, the steps of the cellulose nonwoven fabric modification treatment are as follows:
soaking the cellulose non-woven fabric in acetone for 2-4h, performing ultrasonic treatment for 30-50min, and drying at 100-110 deg.C to constant weight to obtain cleaned cellulose non-woven fabric;
dissolving cerous nitrate in deionized water, adding the cleaned cellulose non-woven fabric and a nitric acid solution with the concentration of 0.025-0.05mol/L, and stirring and mixing uniformly to obtain a system a;
dissolving cedrene alcohol in absolute ethyl alcohol to obtain a system b; and adding the system b into the system a, stirring for reaction, washing, performing suction filtration, and drying to constant weight to obtain the modified cellulose non-woven fabric.
It is further noted that, in some embodiments of the present invention, the cerium nitrate is 0.15 to 0.45 parts, the deionized water is 50 to 100 parts, the cleaned cellulose nonwoven fabric is 1 to 3 parts, the nitric acid solution is 0.2 to 0.5 part, the cedrene alcohol is 0.75 to 1.25 parts, and the absolute ethyl alcohol is 50 to 100 parts by weight.
It is further noted that in some embodiments of the present invention, the stirring reaction temperature is 30-40 deg.C and the reaction time is 5-10h.
According to the invention, cedrene alcohol is firstly adopted to modify the cellulose non-woven fabric, and then the cellulose non-woven fabric is soaked in the antibacterial agent for surface treatment to obtain a modified antibacterial fiber layer, so that the antibacterial property of the antibacterial fiber layer is improved, and the modified antibacterial fiber layer can be used for dressing to reduce the infection of wound wounds; the composite chitosan fiber and chitosan fiber are fixed on the outer layer to prepare the dressing for craniocerebral trauma, which further improves the air permeability and the in vitro coagulation performance of the dressing and further improves the healing effect of the dressing for craniocerebral trauma on wounds.
According to the invention, the modified chitosan is prepared by adopting the isomango alcohol acid modified chitosan, and the chitosan fiber layer is prepared by treating the cellulose non-woven fabric, so that the water absorption performance of the chitosan fiber layer is improved; the chitosan fiber layer is combined with the antibacterial fiber layer and the fixed outer layer to prepare the dressing for craniocerebral trauma, which improves the air permeability and the in-vitro coagulation performance of the dressing for craniocerebral trauma; and can accelerate the healing of the wound. Therefore, the dressing for craniocerebral trauma has better water absorption, antibacterial property and in-vitro coagulation property, and has better healing effect on wounds.
Drawings
FIG. 1 is an IR spectrum of chitosan before and after modification in example 1;
FIG. 2 is an infrared spectrum of the cellulose nonwoven fabric before and after modification in example 5;
FIG. 3 is a graph of the moisture absorption of a chitosan fiber layer;
FIG. 4 is a graph of air permeability for a dressing for craniocerebral trauma;
FIG. 5 is the in vitro coagulation index (BCI) of the dressing for craniocerebral trauma;
fig. 6 is a wound healing rate of the dressing for craniocerebral trauma.
Detailed Description
The technical scheme of the invention is further described in detail by combining the detailed description and the attached drawings; it should be understood, however, that these examples are for the purpose of illustrating the technical solutions of the present invention, and the detailed embodiments and specific procedures are given for further illustrating the features and advantages of the present invention, rather than for limiting the claims of the present invention, and the scope of the present invention is not limited to the following examples. The starting materials used in the present invention are all commercially available unless otherwise specified.
Furthermore, the preparation method of the modified chitosan comprises the following steps: dispersing 2.5-5 parts by weight of chitosan into 20-40 parts by weight of acetic acid solution with the concentration of 2-4wt%, completely dissolving at room temperature, then adding 0.5-1.5 parts by weight of isomango alcohol acid and 0.05-0.1 part by weight of condensing agent, stirring and reacting at room temperature for 3-6h, and washing with distilled water to be neutral to obtain the modified chitosan.
It is further noted that in some embodiments of the present invention, the condensing agent used for modifying chitosan is at least one of DIC, EDC, HOAt, and HOBt.
Further, it is to be noted that the preparation method of the dressing for craniocerebral trauma comprises the following steps:
s1: preparing a chitosan fiber layer: dissolving the modified chitosan in 2-4wt% acetic acid solution to obtain 20-35wt% modified chitosan solution; immersing the cellulose non-woven fabric in the modified chitosan solution, carrying out ultrasonic treatment for 15-30min at the power of 120-200W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing for 30-50min at the normal temperature under the pressure condition of 5-10MPa to obtain a chitosan fiber layer;
s2: preparing an antibacterial fiber layer: immersing the cellulose non-woven fabric in a solution containing an antibacterial agent, wherein the concentration of the antibacterial agent is 5-10wt%, performing ultrasonic treatment for 15-30min at the power of 120-200W, then putting the cellulose non-woven fabric into a hot press, and performing pressure maintaining pressing at the normal temperature under the pressure condition of 5-10MPa for 30-50min to obtain an antibacterial fiber layer;
s3: preparation of the dressing: and fixing the chitosan fiber layer and the antibacterial fiber layer on the outer layer by adopting a binding thread in sequence, sterilizing and packaging to obtain the dressing for craniocerebral trauma.
The specific implementation mode is as follows:
example 1:
a preparation method of a dressing for craniocerebral trauma comprises the following steps:
s1: preparing a chitosan fiber layer: dissolving modified chitosan in 2.5wt% acetic acid solution to obtain 30wt% modified chitosan solution; immersing the cellulose non-woven fabric in the modified chitosan solution, carrying out ultrasonic treatment for 20min at the power of 180W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at the normal temperature under the pressure condition of 8MPa for 30min to obtain a chitosan fiber layer;
s2: preparing an antibacterial fiber layer: immersing the cellulose non-woven fabric in a solution containing ampicillin, wherein the concentration of ampicillin is 7.5wt%, carrying out ultrasonic treatment for 20min at 180W power, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at normal temperature under the pressure condition of 8MPa for 35min to obtain an antibacterial fiber layer;
s3: preparation of the dressing: and fixing the chitosan fiber layer and the antibacterial fiber layer on the outer layer of the cap-shaped net structure by adopting a binding line according to the required size, sterilizing and packaging to obtain the dressing for craniocerebral trauma.
Specifically, in this embodiment, the preparation method of the modified chitosan comprises: dispersing 4.5 parts by weight of chitosan (the deacetylation degree is 90%, and the molecular weight is 2500 Da) in 30 parts by weight of acetic acid solution with the concentration of 2.5wt%, completely dissolving at room temperature, adding 1.2 parts by weight of isomango alcohol acid and 0.075 part by weight of condensing agent, stirring and reacting at room temperature for 4 hours, and washing with distilled water until the solution is neutral to obtain the modified chitosan.
Example 2:
a method for preparing a dressing for craniocerebral trauma, which is different from the preparation method of the dressing in the embodiment 1:
step S1: preparing a chitosan fiber layer: dissolving modified chitosan into 2.5wt% acetic acid solution to prepare 35wt% modified chitosan solution; immersing the cellulose non-woven fabric in the modified chitosan solution, carrying out ultrasonic treatment for 30min at the power of 150W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at the normal temperature under the pressure condition of 6MPa for 40min to obtain the chitosan fiber layer.
The preparation method of the modified chitosan was the same as that of example 1.
Example 3:
a method for preparing a dressing for craniocerebral trauma, which is different from the embodiment 1 in that:
step S2: preparing an antibacterial fiber layer: immersing the cellulose non-woven fabric in a solution containing ampicillin, wherein the concentration of ampicillin is 8.5wt%, carrying out ultrasonic treatment for 20min at 200W power, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing for 40min at normal temperature under the pressure condition of 8MPa to obtain the antibacterial fiber layer.
Example 4:
a method for preparing a dressing for craniocerebral trauma, which is different from the embodiment 1 in that:
step S1: preparing a chitosan fiber layer: dissolving chitosan (deacetylation degree of 90% and molecular weight of 2500 Da) in 2.5wt% acetic acid solution to obtain 30wt% chitosan solution; immersing the cellulose non-woven fabric in a chitosan solution, carrying out ultrasonic treatment for 20min at the power of 180W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at the normal temperature under the pressure condition of 8MPa for 30min to obtain a chitosan fiber layer.
Example 5:
a method for preparing a dressing for craniocerebral trauma, which is different from the embodiment 1 in that:
step S2: firstly, modifying the cellulose non-woven fabric; wherein the cellulose non-woven fabric modification treatment comprises the following steps:
immersing the cellulose non-woven fabric in acetone for treatment for 3h, performing ultrasonic treatment for 30min, and drying at 105 ℃ to constant weight to obtain a cleaned cellulose non-woven fabric;
dissolving 0.25 part by weight of cerium nitrate in 70 parts by weight of deionized water, adding 1.5 parts by weight of the cleaned cellulose non-woven fabric and 0.3 part by weight of nitric acid solution with the concentration of 0.045mol/L, and stirring and mixing uniformly at room temperature to obtain a system a;
dissolving 1.05 parts by weight of cedrene alcohol in 80 parts by weight of absolute ethyl alcohol to obtain a system b; and adding the system b into the system a, stirring and reacting for 8 hours at 35 ℃, washing and filtering for 3 times by using ethanol, washing and filtering for 3 times by using distilled water, and drying in a drying oven to constant weight to obtain the modified cellulose non-woven fabric.
Immersing the modified cellulose non-woven fabric in a solution containing ampicillin, wherein the concentration of ampicillin is 7.5wt%, carrying out ultrasonic treatment for 20min at the power of 180W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at the normal temperature under the pressure condition of 8MPa for 35min to obtain the antibacterial fiber layer.
Example 6:
a method for preparing a dressing for craniocerebral trauma, which is different from the embodiment 5 in that:
the steps of the cellulose non-woven fabric modification treatment are as follows:
immersing the cellulose non-woven fabric in acetone for treatment for 3h, performing ultrasonic treatment for 30min, and drying at 105 ℃ to constant weight to obtain a cleaned cellulose non-woven fabric;
dissolving 0.45 part by weight of cerium nitrate in 100 parts by weight of deionized water, adding 2 parts by weight of the cleaned cellulose non-woven fabric and 0.4 part by weight of nitric acid solution with the concentration of 0.045mol/L, and stirring and mixing uniformly at room temperature to obtain a system a;
dissolving 1.25 parts by weight of cedrene alcohol in 80 parts by weight of absolute ethyl alcohol to obtain a system b; and adding the system b into the system a, stirring and reacting for 8 hours at 35 ℃, washing and filtering for 3 times by using ethanol, washing and filtering for 3 times by using distilled water, and drying in a drying oven to constant weight to obtain the modified cellulose non-woven fabric.
The other steps were the same as in example 5.
Example 7:
a method for preparing a dressing for craniocerebral trauma, which is different from the embodiment 4 in that:
step S2: firstly, modifying the cellulose non-woven fabric; wherein the cellulose non-woven fabric is modified by the following steps:
immersing the cellulose non-woven fabric in acetone for treatment for 3h, performing ultrasonic treatment for 30min, and drying at 105 ℃ to constant weight to obtain a cleaned cellulose non-woven fabric;
dissolving 0.25 part by weight of cerium nitrate in deionized water, adding 1.5 parts by weight of the cleaned cellulose non-woven fabric and 0.3 part by weight of nitric acid solution with the concentration of 0.045mol/L, and stirring and mixing uniformly at room temperature to obtain a system a;
dissolving 1.05 parts by weight of cedrene alcohol in 80 parts by weight of absolute ethyl alcohol to obtain a system b; and adding the system b into the system a, stirring and reacting for 8 hours at 35 ℃, washing and filtering for 3 times by using ethanol, washing and filtering for 3 times by using distilled water, and drying in a drying oven to constant weight to obtain the modified cellulose non-woven fabric.
Immersing the modified cellulose non-woven fabric in a solution containing ampicillin, wherein the concentration of ampicillin is 7.5wt%, carrying out ultrasonic treatment for 20min at the power of 180W, then putting the cellulose non-woven fabric into a hot press, and carrying out pressure maintaining pressing at the normal temperature under the pressure condition of 8MPa for 35min to obtain the antibacterial fiber layer.
Example 8:
1. infrared structural characterization
And performing infrared characterization on the chitosan before and after modification and the cellulose non-woven fabric before and after modification by using a Fourier transform infrared spectrometer (Nicolet-6700 type).
FIG. 1 is an infrared spectrum of chitosan before and after modification in example 1; curves a and b are respectively infrared spectrograms of chitosan and modified chitosan; as can be seen from FIG. 1, 1025cm is in the IR spectrum of chitosan -1 The characteristic absorption peak appearing nearby is the stretching vibration of C-O-C; 870cm -1 The characteristic absorption peak appeared nearby is primary amine-NH 2 The stretching vibration of (2); at 1700cm -1 Stretching vibration with a characteristic absorption peak of C = O appearing nearby; at 1650cm -1 、1550cm -1 The characteristic absorption peaks appeared nearby are C = O in the amide I band and N-H stretching vibration of the amide II band, respectively. Therefore, the modified chitosan is prepared by adopting the isomango alcohol acid modified chitosan.
FIG. 2 is an IR spectrum of the cellulose nonwoven fabric before and after modification in example 5; curves c and d are respectively infrared spectrograms of the cellulose non-woven fabric and the modified cellulose non-woven fabric; as can be seen from FIG. 2, the modified cellulose nonwoven fabric was found to be 2850cm in comparison with the unmodified cellulose nonwoven fabric -1 The absorption peak of C-H symmetrical characteristic appeared nearby is enhanced; at 1450cm -1 The C-H bending vibration absorption peak appeared nearby is enhanced, which indicates that the modified fiber non-woven fabric is prepared by grafting copolymerization of cedrene alcohol and cellulose non-woven fabric.
2. Water absorption Performance test
The water absorption performance of the chitosan fiber layer is measured by adopting a weighing method, firstly, the chitosan fiber layer is cut into the size of 15mm multiplied by 15mm, the chitosan fiber layer is placed in a drying box to be dried to constant weight, and then the weight of the chitosan fiber layer is weighed and recorded as W 0 Then soaked in PBS buffer of pH 7.4Treating in the solution for 24h, taking out the chitosan fiber layer, weighing and recording as W 1 The formula for calculating the moisture absorption rate is as follows:
moisture absorption (%) = (weight after liquid absorption-weight before liquid absorption)/weight before liquid absorption × 100%
Test samples: the untreated cellulose nonwoven fabric, the chitosan fiber layer in example 1, the chitosan fiber layer in example 2, and the chitosan fiber layer in example 4 are denoted as M1, M2, M3, and M4, respectively.
FIG. 3 is a graph of the moisture absorption rate of a chitosan fiber layer; as can be seen from fig. 3, the moisture absorption rate of the chitosan fiber layer in examples 1-2 is higher than 980%, comparing example 1 with example 4, the untreated cellulose nonwoven fabric, and the moisture absorption rate of the chitosan fiber layer in example 1 is higher than that of example 4, the untreated cellulose nonwoven fabric, which shows that the water absorption performance of the chitosan fiber layer is improved by preparing the modified chitosan by using isomango alcohol acid modified chitosan, and treating the cellulose nonwoven fabric to prepare the chitosan fiber layer.
3. Test of antibacterial Property
Placing 60ml PBS buffer solution and 1/400 nutrient broth mixed solution in a conical flask, adding appropriate amount of glass beads, respectively inoculating Escherichia coli and Staphylococcus aureus after high temperature sterilization, fully shaking and mixing to make the concentration of strain suspension be 10 6 CFU/mL；
Test samples: the experiment without the sample is used as a blank control group; adding unmodified cellulose non-woven fabric as a negative control group; an antibacterial fiber layer (antibacterial fiber layer in example 1, antibacterial fiber layer in example 3, antibacterial fiber layer in example 5) was added as an experimental group, and test samples were cut into samples having a size of 4mm × 4mm, and 0.25g was weighed as a test sample.
Oscillation antibacterial experiment: adding 30mL of physiological saline and 1/400 of nutrient broth mixed solution into the Erlenmeyer flask, sterilizing, using as a negative control group or adding 0.25g of sample, adding 0.15mL of bacterial solution into the Erlenmeyer flask by using a pipette, and sealing; oscillating at 25 ℃ for 20min at a rate of 180 r/min; the bacterial suspension remaining in the flask was serially diluted to an appropriate dilution by 10-fold dilution. And (3) pouring 15mL of nutrient agar culture medium into a 0.15mL dish of the original bacterial suspension and the diluent with a proper multiple, and uniformly mixing. After the solid phase is solidified, the plate is inverted and placed in a constant temperature incubator at the temperature of 37 +/-2 ℃, and bacterial colonies are counted after 24 hours of culture. The formula for calculating the antibacterial rate is as follows:
R（%）=（A-B）/A×100%
in the formula: r is antibacterial rate,%; a is the average number of recovered colonies of a negative control group, CFU/mL; b is the average number of recovered colonies in the experimental group, CFU/mL.
TABLE 1 antimicrobial Properties of the antimicrobial fiber layer
As can be seen from table 1, the antibacterial rate of the antibacterial fiber layer in example 1, example 3 and example 5 to escherichia coli is higher than 95.5%, and the antibacterial rate of staphylococcus aureus is higher than 96.5%, comparing the negative control group, example 1 and example 5, the antibacterial rate of escherichia coli and staphylococcus aureus in example 5 is higher than that of the negative control group and example 1, which indicates that the cellulose nonwoven fabric is modified by cedrenol, and then soaked in the antibacterial agent for surface treatment, so as to obtain the modified antibacterial fiber layer, which improves the antibacterial performance of the antibacterial fiber layer, and when the modified antibacterial fiber layer is used in a dressing, the infection of a wound surface can be reduced.
4. Test for air permeability
Cutting a test sample into 6cm multiplied by 6cm according to GB/T5453-1997, and selecting a nozzle with the size phi 8; the YG461E computerized ventilation apparatus was then used to perform the ventilation test on the dressing sample.
Test samples: the dressing for craniocerebral trauma of examples 1-7; respectively denoted as N1, N2, N3, N4, N5, N6, N7.
FIG. 4 is a graph showing the air permeability of a dressing for craniocerebral trauma; as can be seen from FIG. 4, the air permeability of the dressing for craniocerebral trauma in examples 1-3 is not less than 1875mm/s, the air permeability of the dressing for craniocerebral trauma in example 1 is higher than that of example 4 compared with example 1 and example 4, which shows that the modified chitosan prepared by the isomango alkyd modified chitosan is used for preparing the chitosan fiber layer after the cellulose non-woven fabric is treated, and the chitosan fiber layer is combined with the antibacterial fiber layer and the fixing outer layer to prepare the dressing for craniocerebral trauma, so that the air permeability of the dressing is improved; examples 5 to 6 the air permeability of the dressing for craniocerebral trauma is higher than 2158mm/s, and the air permeability of the dressing for craniocerebral trauma in example 1 and example 5, example 4 and example 7, and the air permeability of the dressing for craniocerebral trauma in example 5 is higher than that of example 1, and the air permeability of the dressing for craniocerebral trauma in example 7 is higher than that of example 4, which shows that the dressing for craniocerebral trauma is prepared by modifying cellulose non-woven fabrics by cedrol, then soaking the cellulose non-woven fabrics in an antibacterial agent for surface treatment to obtain a modified antibacterial fiber layer, and then compounding and fixing the modified antibacterial fiber layer with chitosan fibers on the outer layer, and the air permeability of the dressing is further improved.
5. In vitro coagulation performance test
Test samples: the craniocerebral trauma dressings and commercially available medical gauze (available from luohua medical devices industries, ltd., guangzhou, infra) of examples 1-7; respectively denoted as K1, K2, K3, K4, K5, K6, K7, K8.
Cutting a test sample into a square size of 0.5cm multiplied by 0.5cm, putting the square size into a beaker, bathing for 8min at 37 ℃, adding 60 mu L of fresh anticoagulated rabbit blood, then adding 25 mu L of calcium chloride solution with the concentration of 0.25mol/L, incubating for 10min at 37 ℃, adding 30mL of deionized water, shaking and incubating for 5min at a constant temperature of 37 ℃ and 50r/min, taking supernatant, and measuring the light absorption value at 540 nm; the blank group is that 60 mu L of fresh anticoagulated rabbit blood is added into 30mL of deionized water, the light absorption value at 540nm is measured, and the in vitro coagulation index (BCI) is calculated, wherein the lower the BCI value is, the better the coagulation effect is; the calculation formula is as follows:
BCI（%）=A sample (I) /A Blank space ×100%
FIG. 5 is the in vitro coagulation index (BCI) of the dressing for craniocerebral trauma; as can be seen from FIG. 5, the dressing for craniocerebral trauma in examples 1-3 had an in vitro coagulation index (BCI) of less than 31%, much lower than that of commercially available medical gauze; comparing the embodiment 1 with the embodiment 4, wherein the in vitro Blood Coagulation Index (BCI) of the dressing for craniocerebral trauma in the embodiment 1 is lower than that in the embodiment 4, the embodiment shows that the modified chitosan prepared by the isomango alkyd modified chitosan is used for treating the cellulose non-woven fabric to prepare the chitosan fiber layer, and the chitosan fiber layer is combined with the antibacterial fiber layer and the fixed outer layer to prepare the dressing for craniocerebral trauma, so that the in vitro blood coagulation effect of the dressing is improved, and a better hemostatic effect is achieved; examples 5 to 6 the dressing for craniocerebral trauma has an in vitro Blood Coagulation Index (BCI) lower than 27%, and the dressing for craniocerebral trauma in comparative examples 1 and 5, 4 and 7, and 5 has an in vitro Blood Coagulation Index (BCI) lower than that of example 1, and 7 has an in vitro Blood Coagulation Index (BCI) lower than that of example 4, which shows that the dressing for craniocerebral trauma is prepared by modifying a cellulose nonwoven fabric with cedrenol, then soaking the cellulose nonwoven fabric in an antibacterial agent for surface treatment to obtain a modified antibacterial fiber layer, and then compounding and fixing the modified antibacterial fiber layer with chitosan fibers on an outer layer to obtain the dressing for craniocerebral trauma, wherein the dressing for craniocerebral trauma further improves the hemostatic performance.
6. Wound healing Performance test
8 healthy SD male rats were selected and randomly divided into 4 groups of 4d, 6d, 8d, 10d after surgery, 2 in each group. Rats were anesthetized with 3% pentobarbital sodium solution by intraperitoneal injection at 1.5 μ L/g, and the backs were dehaired after anesthesia and sterilized with iodophor and 80% ethanol. 3 round wound surfaces with the diameter of 10mm are prepared on the back of a rat by taking a puncher with the diameter of 10mm, and are wounded to a fascia layer. 1 wound surface of each rat was applied with a dressing for craniocerebral trauma, 1 wound surface was applied with a commercially available medical gauze (purchased from luohua medical instruments industry ltd., guangzhou), the dressing was covered with a PU film, and the dressing was fixed with a medical adhesive tape. Rats were housed in single cages, and wounds were disinfected and replaced with new dressings at 4d, 6d, 8d, and 10 d.
Respectively anaesthetizing rats in corresponding groups at 4d, 6d, 8d and 10d after operation, shooting the size of the wound surface by using a camera, observing the wound healing condition of each group of animals, measuring the area of the wound surface by using Image software, and calculating the wound healing rate by using the following calculation formula:
rate of healing (%) = [ (a) 0 -A t ）/ A 0 ]×100%
In the formula: a. The 0 The original wound surface area is obtained; a. The t The area of the unhealed wound surface.
Test samples: the craniocerebral trauma dressings in example 1, example 4, example 5 and example 7 were marked as Y1, Y2, Y3, Y4 and Y5, respectively, using commercially available medical gauze as a control group.
FIG. 6 is a graph of wound healing rates for a dressing for craniocerebral trauma; as can be seen from fig. 6, the wound healing rate gradually increased with increasing time; the wound healing rate of the craniocerebral trauma dressings in the embodiments 1, 4, 5 and 7 is higher than that of the commercially available medical gauze, which shows that the craniocerebral trauma dressings prepared by the invention have higher wound healing rate and can accelerate wound healing; comparing example 1 with example 4, the wound healing rate of the dressing for craniocerebral trauma in example 1 is higher than that in example 4, which shows that the dressing for craniocerebral trauma is prepared by preparing modified chitosan by using isomango alcohol acid modified chitosan, treating cellulose non-woven fabric to prepare a chitosan fiber layer, and combining the chitosan fiber layer with an antibacterial fiber layer and a fixing outer layer, the wound healing rate of the dressing is improved, and the wound healing can be better promoted; comparing example 1 with example 5, example 4 with example 7, the wound healing rate of the dressing for craniocerebral trauma in example 5 is higher than that of example 1, and the wound healing rate of the dressing for craniocerebral trauma in example 7 is higher than that of example 4, which shows that the dressing for craniocerebral trauma is prepared by modifying cellulose non-woven fabric by cedrol, then soaking the cellulose non-woven fabric in an antibacterial agent for surface treatment to obtain a modified antibacterial fiber layer, and compounding and fixing the modified antibacterial fiber layer with chitosan fibers on the outer layer, and the dressing for craniocerebral trauma further improves the healing effect of the dressing for craniocerebral trauma on wounds.
Conventional operations in the operation steps of the present invention are well known to those skilled in the art and will not be described herein.
The above embodiments are merely illustrative, and not restrictive, and those skilled in the art can make various changes and modifications without departing from the spirit and scope of the invention. Therefore, all equivalent technical solutions also belong to the scope of the present invention, and the protection scope of the present invention should be defined by the claims.
Claims (9)
1. A dressing for craniocerebral trauma, the dressing structure comprising: fixing the outer layer; the chitosan fiber layer is used as a middle layer; the antibacterial fiber layer is used as an inner layer;
the chitosan fiber layer is prepared by soaking cellulose non-woven fabrics in a modified chitosan solution;
the modified chitosan is prepared by modifying chitosan with iso-mango alkyd.
2. A craniocerebral trauma dressing according to claim 1, which is characterized in that: the fixed outer layer is made of elastic cotton thread; the shape is a hat-shaped net structure.
3. The method for preparing a dressing for craniocerebral trauma according to claim 1, which comprises the following steps:
s1: preparing a chitosan fiber layer: dissolving modified chitosan in acetic acid solution to prepare modified chitosan solution; soaking the cellulose non-woven fabric into the modified chitosan solution for ultrasonic treatment, and then placing the cellulose non-woven fabric into a hot press for pressure maintaining and pressing to obtain a chitosan fiber layer;
s2: preparing an antibacterial fiber layer: soaking the cellulose non-woven fabric in a solution containing an antibacterial agent for ultrasonic treatment, and then placing the cellulose non-woven fabric in a hot press for pressure maintaining and pressing to obtain an antibacterial fiber layer;
s3: preparation of the dressing: and fixing the chitosan fiber layer and the antibacterial fiber layer on the outer layer by adopting a binding wire in sequence, and sterilizing and packaging to obtain the craniocerebral trauma dressing.
4. The method for preparing a dressing for craniocerebral trauma according to claim 3, which is characterized in that: the preparation method of the modified chitosan comprises the following steps: dispersing chitosan in acetic acid solution, dissolving completely at room temperature, adding isomango alcohol acid and a condensing agent, stirring at room temperature for reaction, and washing to be neutral to obtain the modified chitosan.
5. The method for preparing a dressing for craniocerebral trauma according to claim 4, which is characterized in that: according to the parts by weight, the chitosan is 2.5-5 parts, the acetic acid solution is 20-40 parts, the isomango alcohol acid is 0.5-1.5 parts, and the condensing agent is 0.05-0.1 part.
6. The method for preparing a dressing for craniocerebral trauma according to claim 3, which is characterized in that: in the step S1, the concentration of the modified chitosan solution is 20-35wt%.
7. The method for preparing a dressing for craniocerebral trauma according to claim 3, which is characterized in that: in the step S2, the antibacterial agent is at least one of ampicillin, cefoperazone, levofloxacin, doxycycline, roxithromycin, azithromycin, ciprofloxacin and lomefloxacin.
8. The method for preparing a dressing for craniocerebral trauma according to claim 3, which is characterized in that: in the step S2, the ultrasonic treatment power is 120-200W, and the ultrasonic treatment time is 15-30min.
9. Use of the modified chitosan of claim 1 for increasing the air permeability of a dressing for craniocerebral trauma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211188318.8A CN115364268A (en) | 2022-09-28 | 2022-09-28 | Dressing for craniocerebral trauma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211188318.8A CN115364268A (en) | 2022-09-28 | 2022-09-28 | Dressing for craniocerebral trauma and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115364268A true CN115364268A (en) | 2022-11-22 |
Family
ID=84073457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211188318.8A Pending CN115364268A (en) | 2022-09-28 | 2022-09-28 | Dressing for craniocerebral trauma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115364268A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050240137A1 (en) * | 2004-02-23 | 2005-10-27 | Zhu Yong H | Hemostatic agent for topical and internal use |
| CN109893342A (en) * | 2019-04-08 | 2019-06-18 | 佳木斯大学附属第一医院 | A kind of craniocerebral trauma dressing and preparation method thereof |
| CN111035801A (en) * | 2020-01-14 | 2020-04-21 | 青岛科技大学 | Silver nanocluster based chitosan hydrogel dressing and preparation method and application thereof |
| CN111991606A (en) * | 2020-08-07 | 2020-11-27 | 广东职业技术学院 | Micro-nano alginate fiber dressing and preparation method thereof |
| CN112791223A (en) * | 2020-12-30 | 2021-05-14 | 河南亚都实业有限公司 | Antibacterial chitosan-based hemostatic patch |
| CN113106623A (en) * | 2021-04-07 | 2021-07-13 | 宁波因天之序生物科技有限公司 | Anti-infection composite layer medical dressing, bed sheet and application |
-
2022
- 2022-09-28 CN CN202211188318.8A patent/CN115364268A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050240137A1 (en) * | 2004-02-23 | 2005-10-27 | Zhu Yong H | Hemostatic agent for topical and internal use |
| CN109893342A (en) * | 2019-04-08 | 2019-06-18 | 佳木斯大学附属第一医院 | A kind of craniocerebral trauma dressing and preparation method thereof |
| CN111035801A (en) * | 2020-01-14 | 2020-04-21 | 青岛科技大学 | Silver nanocluster based chitosan hydrogel dressing and preparation method and application thereof |
| CN111991606A (en) * | 2020-08-07 | 2020-11-27 | 广东职业技术学院 | Micro-nano alginate fiber dressing and preparation method thereof |
| CN112791223A (en) * | 2020-12-30 | 2021-05-14 | 河南亚都实业有限公司 | Antibacterial chitosan-based hemostatic patch |
| CN113106623A (en) * | 2021-04-07 | 2021-07-13 | 宁波因天之序生物科技有限公司 | Anti-infection composite layer medical dressing, bed sheet and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1859816B1 (en) | The preparing method and the use of antiseptic medical dressing | |
| JP6974177B2 (en) | Composition for wound dressing | |
| CN105797193B (en) | A kind of Thermo-sensitive arginine base long acting antibiotic aerogel dressing and preparation method thereof | |
| CN118846182A (en) | Composition for wound dressing | |
| CN109010897B (en) | Preparation method of medical antibacterial gel dressing | |
| CN112480434B (en) | A kind of copper ion antibacterial hydrogel and preparation method and application | |
| CN1833731A (en) | Making method of and use of antibiotic surgical dressing | |
| CN102813957A (en) | Biological membrane which promotes healing and preparation method thereof | |
| CN114949325A (en) | A kind of preparation method of composite nanofiber membrane for wound dressing and composite nanofiber membrane | |
| CN114014953A (en) | Functionalized chitosan microsphere and preparation method and application thereof | |
| Singh et al. | Chitin membrane for wound dressing application–preparation, characterisation and toxicological evaluation | |
| AU2021105727A4 (en) | A method of preparation of Silk Fibroins coated with Hybrid chitosan-ZnO nanoparticles for wound dressing. | |
| CN112741929B (en) | Medical trauma hemostasis composite dressing | |
| CN106512063A (en) | Preparing method of silver-containing anti-bacterial dressing | |
| CN109875762A (en) | A new type of antibacterial band-aid and its preparation method and application | |
| CN115364268A (en) | Dressing for craniocerebral trauma and preparation method thereof | |
| CN115845114B (en) | Nanofiber medical wound dressing and preparation method thereof | |
| CN113106623B (en) | Anti-infection composite layer medical dressing, bed sheet and application | |
| CN108498842A (en) | A kind of medical dressing and preparation method thereof for external Wound care | |
| JPH10151184A (en) | Functional wound protective material | |
| JP2001333973A (en) | Antibacterial sheet of active carbon and antibacterial deodorant covering material for wound | |
| CN114306729A (en) | Biological antibacterial film-forming liquid medical dressing and preparation method thereof | |
| CN116832204B (en) | APNO-loaded polyhydroxyethyl acrylamide hydrogel and preparation method thereof | |
| CN108904530B (en) | Nano-silver bactericidal hemostatic composition | |
| CN114452433B (en) | Medical dressing, preparation method, application and wound dressing plaster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |